Literature DB >> 17822455

Fracture risk in Danish men with prostate cancer: a nationwide register study.

Bo Abrahamsen1, Morten F Nielsen, Peter Eskildsen, Jens Thorup Andersen, Steen Walter, Kim Brixen.   

Abstract

OBJECTIVE: To assess the risk of fracture attributable to prostate cancer, and the impact of exposure to prescribed gonadotrophin-releasing hormone agonists and antiandrogens on this risk in a nationwide, population-based case-control study. PATIENTS AND METHODS: Data from the Danish National Hospital Discharge Register, the National Bureau of Statistics, and the National Prescriptions Database were merged. The analysis covered 15 716 men aged >50 years presenting with a fracture at any hospital in Denmark in 2000, and 47 149 age-matched control men. A previous diagnosis of prostate cancer had been recorded in 1.3% of controls and 2.5% of those with a fracture.
RESULTS: Prostate cancer was associated with an increased odds ratio (95% confidence interval) for all fractures of 1.8 (1.6-2.1), for hip fractures of 3.7 (3.1-4.4), but no increased risk of vertebral fractures. The increased fracture risk became apparent early after diagnosis and remained pronounced even in long-term survivors. Androgen deprivation therapy (ADT) with an odds ratio of 1.7 (1.2-2.5; P < 0.01) and orchidectomy, at 1.7 (1.2-2.4; P < 0.01) added to the overall fracture risk. In all, 3.1% of hip fractures in Danish men aged >50 years are attributable to prostate cancer.
CONCLUSION: Prostate cancer, orchidectomy and the use of ADT are associated with a markedly greater risk of fractures, especially of the hip. The risk of hip fracture is not confined to the very old, neither is the risk made negligible by the excess mortality in patients with advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822455     DOI: 10.1111/j.1464-410X.2007.07163.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

1.  Correlates of trabecular and cortical volumetric BMD in men of African ancestry.

Authors:  Yahtyng Sheu; Jane A Cauley; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Christopher L Gordon; Candace M Kammerer; Joseph M Zmuda
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

2.  Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Ronald A Morton; Michael L Hancock; K Gary Barnette; Mitchell S Steiner; Matthew R Smith
Journal:  J Urol       Date:  2011-06-15       Impact factor: 7.450

3.  Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.

Authors:  Jennifer L Beebe-Dimmer; Karynsa Cetin; Vahakn Shahinian; Hal Morgenstern; Cecilia Yee; Kendra L Schwartz; John Acquavella
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-11-24       Impact factor: 2.890

Review 4.  Contemporary role of androgen deprivation therapy for prostate cancer.

Authors:  Vincenzo Pagliarulo; Sergio Bracarda; Mario A Eisenberger; Nicolas Mottet; Fritz H Schröder; Cora N Sternberg; Urs E Studer
Journal:  Eur Urol       Date:  2011-08-19       Impact factor: 20.096

5.  Hip fracture epidemiological trends, outcomes, and risk factors, 1970-2009.

Authors:  Ray Marks
Journal:  Int J Gen Med       Date:  2010-04-08

6.  The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer.

Authors:  Jennifer L Quon; James B Yu; Pamela R Soulos; Cary P Gross
Journal:  J Geriatr Oncol       Date:  2013-01       Impact factor: 3.599

7.  Prostate cancer and osteoporosis.

Authors:  Stephen P Tuck; Birgit Hanusch; Julie Walker; Harish K Datta
Journal:  Curr Osteoporos Rep       Date:  2013-03       Impact factor: 5.096

8.  Predictors of the rate of BMD loss in older men: findings from the CHAMP study.

Authors:  K Bleicher; R G Cumming; V Naganathan; M J Seibel; F M Blyth; D G Le Couteur; D J Handelsman; H M Creasey; L M Waite
Journal:  Osteoporos Int       Date:  2012-12-05       Impact factor: 4.507

9.  Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study.

Authors:  Andrew M McDonald; Eddy S Yang; Kenneth G Saag; Emily B Levitan; Nicole C Wright; John B Fiveash; Soroush Rais-Bahrami; Smita Bhatia
Journal:  Arch Osteoporos       Date:  2020-02-29       Impact factor: 2.617

Review 10.  The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Authors:  Peter Busch Østergren; Caroline Kistorp; Finn Noe Bennedbæk; Jens Faber; Jens Sønksen; Mikkel Fode
Journal:  Nat Rev Urol       Date:  2016-04-26       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.